Medivir AB (LTS:0GP7) Other Gross PPE : kr11.70 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Medivir AB Other Gross PPE?

Medivir AB's Other Gross PPE for the quarter that ended in Mar. 2024 was kr11.70 Mil.

Medivir AB's quarterly Other Gross PPE declined from Sep. 2023 (kr13.00 Mil) to Dec. 2023 (kr0.59 Mil) but then increased from Dec. 2023 (kr0.59 Mil) to Mar. 2024 (kr11.70 Mil).

Medivir AB's annual Other Gross PPE declined from Dec. 2021 (kr0.59 Mil) to Dec. 2022 (kr0.59 Mil) but then increased from Dec. 2022 (kr0.59 Mil) to Dec. 2023 (kr0.59 Mil).

Medivir AB Other Gross PPE Historical Data

The historical data trend for Medivir AB's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Other Gross PPE Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

0.59

Medivir AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial															14.10	13.70	13.00	0.59	11.70

Medivir AB Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Medivir AB (LTS:0GP7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (LTS:0GP7) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

Medivir AB (LTS:0GP7) Headlines

No Headlines